Chapters

Transcript

Video

Given the ARTISTRY-1 trial, how would you envision the role of nemvaleukin within the larger context of immunotherapy? How should cytokines be sequenced in the therapeutic pathway for refractory patients such as those evaluated in ARTISTRY-1?


Created by

CMEducation Resources | iQ&A Cytokine Immunotherapy Intelligence Zone

Presenter

Ulka Vaishampayan, MBBS

Ulka Vaishampayan, MBBS

Professor of Internal MedicineDirector, Phase I ProgramRogel Cancer CenterUniversity of MichiganAnn Arbor, MI